Kara B Markham

Dr. Kara B Markham

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2024 in Journal of Patient Experience
Verified
Journal Article
Open access
EGEmily J Gregory
Emily J Gregory
AAAleeza H Abbasi
Aleeza H Abbasi
KMKara B Markham
Kara B Markham
Recognizing the paucity of literature describing the non-medical effects of care at a tertiary parental fetal care center upon families, the purpose of the study was to better examine the potential barriers that our patients face related to care in a parental fetal care center. An anonymous survey was sent via email to patients who received care from 2015 to 2021. The survey included questions regarding demographics, fetal diagnoses, non-medical expenses related to care, and the impact of care on patient relationships, employment, and other children. 453 patients (15.9%) responded out of the 2684 emails sent. 58.3% of patients traveled >100 miles to reach our referral center, with 20% traveling >300 miles. 42.6% of patients reported non-medical expenditures exceeding $1000, with nearly 1 in 10 reporting expenditures of >$5000 (8.6%). Overall, 38.2% of women reported moderate to severe financial burdens related to receiving care at the parental fetal care center. This study illuminates the financial and social burdens that care at a tertiary parental fetal care center imposes upon families. By acknowledging these barriers, we can strive to minimize them to best provide equitable access to high-quality fetal care services.

22 June 2025 in Children
Verified
Journal Article
Open access
PDF file
MSMolly R Sherwood
Molly R Sherwood
BWBethany M. Weathersby
Bethany M. Weathersby
MHMarion Granger Howard
Marion Granger Howard
KMKara B Markham
Kara B Markham
Background/Objectives: Pregnancies complicated by red cell alloimmunization can progress to hemolytic disease of the fetus and newborn (HDFN), requiring close monitoring and timely intervention to prevent fetal/neonatal morbidity and mortality. This study investigated disease presentation, interventions, and outcomes in respondents with a history of alloimmunized pregnancy. Methods: This was a retrospective cross-sectional survey study administered online to alloimmunized patients between November 2022–February 2023. A total of 127 participants reported on 200 alloimmunized pregnancies. Distribution of pregnancy characteristics, antibodies and titers, monitoring, treatments and fetal outcomes were described and stratified where appropriate by fetal antigen status and disease severity. Outcomes and management practices in subsequent pregnancies following fetal loss to HDFN are reported. Results: Multiple antibodies were present in 42% of pregnancies with known antibody type (80/192). Titers reached critical levels (any titer for Anti-K; ≥16 for all other antibodies) in 71% (125/176) of pregnancies where titer was reported. Among fetal antigen positive pregnancies with critical titers, intrauterine transfusions were conducted in 40% (42/106), intravenous immunoglobulin was administered in 14% (15/106), plasmapheresis in 7% (7/106), and phenobarbital in 9% (9/106). Complications from transfusion were reported in 38% of pregnancies receiving intrauterine transfusion (17/45). Fetal death due to HDFN or complications from intrauterine transfusion was reported in 9% of antigen positive pregnancies with critical titers (10/106) and 16% of pregnancies receiving intrauterine transfusion (7/45). Conclusions: Disease presentation and severity complements previous research in this disease population, however, monitoring practices were diverse. Fetal death and intrauterine complication rates were higher than those previously reported in large international referral centers. Development of best practices and centralized referral centers may improve disease outcomes.

10 December 2025 in Transfusion Medicine and Hemotherapy
Verified
Journal Article
Open access
SDSuzanne Dysart
Suzanne Dysart
BFBraxton Forde
Braxton Forde
MTMamie Thant
Mamie Thant
JLJames Liu
James Liu
SSSara Staker
Sara Staker
KMKara B Markham
Kara B Markham
Objective: The aim of the study was to compare the relationship between titer concentrations via gel microcolumn assay (GMA) and conventional tube testing (CTT) methods at a single institution that serves as a referral center for women at risk for hemolytic disease of the fetus and newborn. Study Design: Retrospective chart review on all obstetric patients treated was conducted at a single tertiary care center with RBC antibodies from November 2018 to October 2022. Patients were included in the statistical analysis if there were parallel CTT and GMA titration studies available. GMA vs. CTT titers were graphed via bubble plots, and polynomial regression analysis was used to evaluate the correlation between the two methods. Logistical regression was used to evaluate the sensitivity and specificity of GMA titers for prediction of a critical CTT titer of 16. Results: A total of 166 GMA titers from 87 patients had corresponding CTT titers. The most common antibody was anti-D (76) followed by anti-K (29). Polynomial regression indicated a relationship between GMA titers and CTT titers (R2 = 0.5325, p < 0.001). The relationship changed significantly with removal of anti-K antibodies (R2 = 0.6733, p < 0.001). GMA titers were predictive of a critical CTT (AUC 0.97, p < 0.001) for non-anti-K antibodies but not predictive for anti-K antibodies (p = 0.134). Overall a GMA titer of 64 was predictive of a CTT titer of 16 or higher with 90.7% (95% CI: 82.5–95.9%) sensitivity and 85.0% (95% CI: 75.3–92.0%) specificity. All GMA results of 32 or higher for anti-K antibodies had CTT of at least 16, whereas the same could not be said of the non-anti-K antibodies until GMA titers reached at least 512. Conclusion: GMA titers are consistently higher than CTT titers in all antibodies tested in our study, and the correlation between the titers is statistically significant for all antibodies except for anti-K. GMA methodology is often preferred as first-line testing by the hospital transfusion service due to cost-effectiveness and ability to be automated. A predictive table was created for provider reference if their hospital’s blood bank employs GMA techniques.

31 January 2024 in The American Journal of Bioethics
Verified
Journal Article
Closed access
SPSamantha Joan Palmaccio-Lawton
Samantha Joan Palmaccio-Lawton
KMKara B Markham
Kara B Markham
MBMaria Barnes-Davis
Maria Barnes-Davis
ELElizabeth Lanphier
Elizabeth Lanphier

14 January 2026 in Prenatal Diagnosis
Verified
Journal Article
Closed access
ELEthan Lorence
Ethan Lorence
KSKatelyn Seither
Katelyn Seither
HHHua He
Hua He
KMKara B Markham
Kara B Markham
BWBeatrix Wong
Beatrix Wong